Hope for a better tomorrow starts today with you.

The MS community needs your help to test first-of-a kind therapy for PPMS and RMS to determine its potential to both reduce relapses as well as slow the progression of the disease.

To learn more about our clinical studies, click below:

Roche is committed to developing cutting-edge treatments to improve the lives of people living with multiple sclerosis. By participating in these studies, you may help create a brighter future for people living with RMS and PPMS.


Multiple Sclerosis Genentech icon

What is MS?

Multiple sclerosis (MS) is a disease that occurs when the body’s immune system behaves abnormally and attacks the brain, spinal cord and optic nerves of the central nervous system (CNS). It is the leading cause of nervous system-related disability in young people, usually striking between 20 and 40 years of age.1 In the US, approximately 400,000 people have this disorder, and women are two to three times more likely to develop MS than men.

There is increasing clinical evidence that MS progresses even when symptoms are not outwardly apparent. Newer MRI techniques and cognitive tests usually show increased disease activity, even if symptoms appear to be in remission.1 At least 90% of people with MS experience disease progression and increased disability within 20 years of onset.2

Although specific symptoms of MS vary among individuals, the disease usually takes one of four courses. These studies will focus on the following two types of MS:

  • Relapsing MS (RMS) is the most common form of MS, with 85% of people initially experiencing episodes of acute symptoms followed by recovery periods. This includes:

    • Relapse-remitting MS (RRMS)
    • Active SPMS (secondary-progressive MS)
  • Primary-progressive MS (PPMS) is a progressive form of the disease that worsens over time; however, the rate of progression is variable. The incidence of PPMS is approximately 15% of MS cases.

How is MS treated?

There is no cure for MS. A combination of therapies is commonly used to help people manage acute symptoms of relapse or reduce disease activity.3

  • Severe relapses are treated with high-dose corticosteroids to decrease inflammation.
  • Other residual symptoms, such as pain or spasticity, may be treated with appropriate medicines.
  • Rehabilitation may also be used to maintain function and ability to perform effectively at home and at work.

None of these strategies cure the disease or prevent future disability.

Several medicines have been approved by the FDA that delay disease progression in MS.3 Though progress has been made in the treatment of MS, new options are needed to help control disease activity and delay, prevent, or reverse disability.


References

  1. Correale J, Ysrraelit MC. Benign Multiple Sclerosis: Does it exist? Curr Neurol Neurosci Rep. 2012;12:601-609.
  2. Hirst C, Ingram G, Swingler R, et al. Change in disability in patients with multiple sclerosis: a 20-year prospective population-based analysis. J Neurol Neurosurg Psychiatry 2008; 79:1137-1143.
  3. National Multiple Sclerosis Society. https://www.nationalmssociety.org/Treating-MS/Medications. Accessed September 2017.

Clinical Trial Information

Information and support about Genentech-sponsored trials:

Time

Hours: Monday–Friday, 5am–5pm PT

Information about these studies is provided on these websites so you can learn about them. This may help you decide whether these studies are right for you. It may also be more useful in your discussions with your doctor, family and caregiver. The information is not intended to be promotional. The drugs being studied have not been approved by the FDA, EMA or other regulatory agency for the disease being studied.